Beximco Pharmaceuticals (BXP) Given Corporate Rating at Northland Securities

Beximco Pharmaceuticals (LON:BXP)‘s stock had its “corporate” rating reiterated by analysts at Northland Securities in a research report issued on Friday, January 19th.

Shares of Beximco Pharmaceuticals (LON BXP) remained flat at $GBX 57.50 ($0.79) during trading on Friday. 35,875 shares of the stock were exchanged, compared to its average volume of 38,146. The company has a market capitalization of $44,830.00 and a PE ratio of 9.60. Beximco Pharmaceuticals has a 1 year low of GBX 50.38 ($0.70) and a 1 year high of GBX 71.75 ($0.99).

ILLEGAL ACTIVITY NOTICE: “Beximco Pharmaceuticals (BXP) Given Corporate Rating at Northland Securities” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/beximco-pharmaceuticals-bxp-rating-reiterated-by-northland-securities.html.

Beximco Pharmaceuticals Company Profile

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. It offers allergic disorder, analgesic and antipyretic, anti-infective, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, intravenous fluid, muscloskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products.

Receive News & Ratings for Beximco Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beximco Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply